keyword
MENU ▼
Read by QxMD icon Read
search

Proton Pump Inhibitors Increase Risk

keyword
https://www.readbyqxmd.com/read/29457492/the-risk-of-community-acquired-enteric-infection-in-proton-pump-inhibitor-therapy-systematic-review-and-meta-analysis
#1
Radwan A Hafiz, Chia Wong, Stuart Paynter, Michael David, Geeske Peeters
BACKGROUND: Previous meta-analyses suggest that users of proton pump inhibitors (PPIs) have a higher risk of developing enteric infections compared with nonusers. These previous meta-analyses have considerable heterogeneity, and it is not clear whether the effect of PPIs is different for different types of microorganisms. OBJECTIVE: The aim of this study is to update previous meta-analyses, concentrating on enteric infection in community settings and exploring potential sources of heterogeneity...
February 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29454848/a-multi-center-derivation-and-validation-of-a-simple-predictive-index-for-healthcare-associated-clostridium-difficile-infection
#2
Meghann L Davis, Harlan G Sparrow, Judy O Ikwuagwu, William L Musick, Kevin W Garey, Katherine K Perez
OBJECTIVES: Clostridium difficile infection (CDI) is the most common cause of healthcare-associated infections in the United States. Despite well-established risk factors, very little research has focused on use of these variables to identify a patient population at high-risk for CDI to target with primary prevention strategies. A predictive index for healthcare-associated CDI could improve clinical care and guide research for primary prevention trials. Our objective was to develop a predictive index to identify patients at high-risk for healthcare-associated CDI...
February 15, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29441500/the-epidemiology-of-clostridium-difficile-infection-in-japan-a-systematic-review
#3
REVIEW
Thomas V Riley, Tomomi Kimura
To increase understanding of the epidemiology, risks, consequences and resource utilization of Clostridium difficile infection (CDI) in Japan, a systematic literature review was undertaken of relevant publications from January 2006 to November 2017. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and methods, 55 articles met the criteria for full review. The majority (58%) of studies were from a single site, with the most recent data from 2015. The incidence, reported prevalence and recurrence rate of CDI in Japan were 0...
February 13, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29436014/comparison-of-dysplastic-fundic-gland-polyps-in-patients-with-and-without-familial-adenomatous-polyposis
#4
Shana F Straub, Michael G Drage, Raul S Gonzalez
AIM: Dysplastic FGPs (d-FGPs) typically arise in patients with familial adenomatous polyposis (FAP) but may occur in nonsyndromic patients. They rarely develop malignancy, but their significance is unclear, especially in nonsyndromic patients. APC/β-catenin alterations have been implicated in their pathogenesis, and β-catenin immunohistochemistry (IHC) may show nuclear positivity. METHODS AND RESULTS: We identified 124 FGPs with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) or indefinite for dysplasia (IFD) from 66 patients (27 with FAP, 39 nonsyndromic)...
February 12, 2018: Histopathology
https://www.readbyqxmd.com/read/29432214/the-association-of-proton-pump-inhibitors-and-chronic-kidney-disease-cause-or-confounding
#5
Tingting Li, Yan Xie, Ziyad Al-Aly
PURPOSE OF REVIEW: To discuss whether the recently described relationship between proton pump inhibitor (PPI) use and the risk of adverse kidney outcomes represents a causal relationship or is merely the result of confounding. RECENT FINDINGS: A wave of observational studies has described an association between PPI use and the risk of development of chronic kidney disease and its progression to end-stage renal disease. The results are generally robust and remarkably consistent across different studies...
February 9, 2018: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/29428498/the-role-of-gut-microbiota-in-clostridium-difficile-infection
#6
REVIEW
Michael Samarkos, Elpida Mastrogianni, Olga Kampouropoulou
Clostridium difficile infection has emerged as a major health problem. Because it is a spore-forming microorganism, C. difficile is difficult to eradicate and recurrences of the infection are frequent. The strong association of CDI with prior use of antibiotics led to the recognition that disturbances in the gut microbiota apparently plays a central role in CDI. Except for antibiotics, several other risk factors for CDI have been recognised, such as advanced age and use of proton pump inhibitors. The common characteristic of these factors is that they are associated with changes in the composition of gut microbiota...
February 7, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29402646/fall-risk-increasing-drugs-a-systematic-review-and-meta-analysis-iii-others
#7
Lotta J Seppala, Esther M M van de Glind, Joost G Daams, Kimberley J Ploegmakers, Max de Vries, Anne M A T Wermelink, Nathalie van der Velde
BACKGROUND AND OBJECTIVE: The use of psychotropic medication and cardiovascular medication has been associated with an increased risk of falling. However, other frequently prescribed medication classes are still under debate as potential risk factors for falls in the older population. The aim of this systematic review and meta-analysis is to evaluate the associations between fall risk and nonpsychotropic and noncardiovascular medications. METHODS AND DESIGN: A systematic review and meta-analysis...
February 2, 2018: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/29397800/electronically-available-comorbid-conditions-for-risk-prediction-of-healthcare-associated-clostridium-difficile-infection
#8
Anthony D Harris, Alyssa N Sbarra, Surbhi Leekha, Sarah S Jackson, J Kristie Johnson, Lisa Pineles, Kerri A Thom
OBJECTIVE To analyze whether electronically available comorbid conditions are risk factors for Centers for Disease Control and Prevention (CDC)-defined, hospital-onset Clostridium difficile infection (CDI) after controlling for antibiotic and gastric acid suppression therapy use. PATIENTS Patients aged ≥18 years admitted to the University of Maryland Medical Center between November 7, 2015, and May 31, 2017. METHODS Comorbid conditions were assessed using the Elixhauser comorbidity index. The Elixhauser comorbidity index and the comorbid condition components were calculated using the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes extracted from electronic medical records...
February 5, 2018: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/29392851/do-fda-label-changes-work-assessment-of-the-2010-class-label-change-for-proton-pump-inhibitors-using-the-sentinel-system-s-analytic-tools
#9
Rachel E Sobel, Andrew Bate, James Marshall, Kevin Haynes, Nandini Selvam, Vinit Nair, Gregory Daniel, Jeffrey S Brown, Robert F Reynolds
PURPOSE: To pilot use of the US Food and Drug Administration's (FDA's) Sentinel System data and analytic tools by a non-FDA stakeholder through the Innovation in Medical Evidence Development and Surveillance system of the Reagan Udall Foundation. We evaluated the US FDA 2010 proton pump inhibitor (PPI) class label change that warned of increased risk of bone fracture, to use PPIs for the lowest dose and shortest duration, and to manage bone status for those at risk for osteoporosis. METHODS: The cohort consisted of adults aged 18 years or older prescribed PPIs without fracture risk factors...
February 2, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29376492/is-the-use-of-proton-pump-inhibitors-a-risk-factor-for-alzheimer-s-disease-molecular-mechanisms-and-clinical-implications
#10
Kazuki Ide, Norihiro Matsuoka, Koji Kawakami
Proton-pump inhibitors (PPIs), such as omeprazole, lansoprazole, and rabeprazole, are used for the treatment of gastroesophageal reflux disease and peptic ulcer disease. The use of PPIs has increased, especially in older individuals, and a pharmacoepidemiological study indicated that the use of PPIs peaks in people aged 80 years or older. In this population, Alzheimer's disease (AD) is a common neurological disorder and type of dementia, occurring with a frequency of approximately 10%. Currently, over 45 million people are estimated to have dementia worldwide, and it is a major cause of death in the elderly...
January 28, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29372020/pain-medication-and-long-qt-syndrome
#11
REVIEW
Christoph Klivinyi, Helmar Bornemann-Cimenti
Long QT syndrome is a cardiac repolarization disorder and is associated with an increased risk of torsades de pointes. The acquired form is most often attributable to administration of specific medications and/or electrolyte imbalance. This review provides insights into the risk for QT prolongation associated with drugs frequently used in the treatment of chronic pain. In the field of pain medicine all the major drug classes (i.e. NSAIDs, opioids, anticonvulsive and antidepressant drugs, cannabinoids, muscle relaxants) contain agents that increase the risk of QT prolongation...
January 2018: Korean Journal of Pain
https://www.readbyqxmd.com/read/29371761/the-influence-of-long-term-use-of-proton-pump-inhibitors-on-the-gut-microbiota-an-age-sex-matched-case-control-study
#12
Tomohisa Takagi, Yuji Naito, Ryo Inoue, Saori Kashiwagi, Kazuhiko Uchiyama, Katsura Mizushima, Saeko Tsuchiya, Tetsuya Okayama, Osamu Dohi, Naohisa Yoshida, Kazuhiro Kamada, Takeshi Ishikawa, Osamu Handa, Hideyuki Konishi, Kayo Okuda, Yoshimasa Tsujimoto, Hiromu Ohnogi, Yoshito Itoh
Proton pump inhibitors (PPIs) are widely used to treat gastro-esophageal reflux and prevent gastric ulcers, and have been considered as low risk. However, recent studies have identified possible associations between PPI use and gut microbiota, suggesting that PPIs use increases the risk of enteric infections, including Clostridium difficile infection. To investigate gut microbiota in Japanese PPIs users, we conducted 16S metagenomics analysis of fecal samples collected from PPI users and healthy adults. In total, 36 PPI users and 36 PPI non-users (as control subjects) matched by age and sex were recruited and fecal samples were obtained to analyze the gut microbiome using 16S rRNA gene sequencing...
January 2018: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/29361091/clostridium-difficle-enteropathy-is-associated-with-a-higher-risk-for-acute-kidney-injury-in-patients-with-an-ileostomy-a-case-control-study
#13
Gursimran Kochhar, Preston Edge, Courtney Blomme, Xian-Rui Wu, Rocio Lopez, Jean Ashburn, Bo Shen
Background: Clostridium difficile infection (CDI) is traditionally considered a colon-affecting disease with frequent pseudomembrane formation. However, multiple case reports have documented the existence of CDI in the small bowel, and the literature on outcome of C difficile enteropathy (CDE) is sparse. The aims of our study are to identify risk factors and to assess patient-related outcomes associated with CDE. Methods: This is a case-control study involving 112 patients at our tertiary care center...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29356784/gastroesophageal-reflux-frequency-severity-age-of-onset-family-history-and-acid-suppressive-therapy-predict-barrett-esophagus-in-a-large-population
#14
Omar Bakr, Wei Zhao, Douglas Corley
GOALS: To identify risk factors associated with Barrett esophagus (BE) for potential improved surveillance and risk reduction. BACKGROUND: Gastroesophageal reflux disease (GERD) is a known risk factor for esophageal adenocarcinoma, but the ability of GERD symptom frequency and severity to predict presence of its putative precursor lesion, BE, is less well-defined in large, community-based populations. STUDY: We conducted a case-control study within the Kaiser Permanente Northern California population...
January 19, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29345406/helicobacter-pylori-infection-and-occurrence-of-celiac-disease-in-subjects-hla-dq2-dq8-positive-a-prospective-study
#15
Maria P Dore, Roberta Salis, Maria F Loria, Vincenzo Villanacci, Gabrio Bassotti, Giovanni M Pes
BACKGROUND: Celiac disease (CD) occurs in subjects positive for HLA-DQ2 and/or DQ8 gene loci at any age following ingestion of gluten-containing food. An increased permeability of the mucosa allows interactions between gliadin macromolecules and genetic factors. It has been observed that Helicobacter pylori has the ability to modulate the integrity of the duodenal epithelium. We aimed to determine whether H. pylori infection may enhance the occurrence of CD in genetically susceptible subjects...
January 18, 2018: Helicobacter
https://www.readbyqxmd.com/read/29343945/the-impact-of-pharmaceutical-interventions-on-the-rational-use-of-proton-pump-inhibitors-in-a-chinese-hospital
#16
Chuanwei Xin, Zhu Dong, Mengmeng Lin, Gong-Hua Li
Background: The prescriptions of proton pump inhibitors (PPIs) have raised concern due to both huge increase in medical expenditure and the possible long-term adverse events caused by them; therefore, an approach to taper off the irrational use of PPIs by patients is clinically warranted. The aim of this study was to evaluate the impact of pharmaceutical interventions on the rational use of PPIs. Patients and methods: A single-center, pre- to post-intervention study (pharmaceutical interventions group and control group) was performed in a Chinese hospital...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29339434/cerebrovascular-outcomes-with-proton-pump-inhibitors-and-thienopyridines-a-systematic-review-and-meta-analysis
#17
Konark Malhotra, Aristeidis H Katsanos, Mohammad Bilal, Muhammad Fawad Ishfaq, Nitin Goyal, Georgios Tsivgoulis
BACKGROUND AND PURPOSE: Pharmacokinetic and prior studies on thienopyridine and proton pump inhibitors (PPI) coadministration provide conflicting data for cardiovascular outcomes, whereas there is no established evidence on the association of concomitant use of PPI and thienopyridines with adverse cerebrovascular outcomes. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials and cohort studies from inception to July 2017, reporting following outcomes among patients treated with thienopyridine and PPI versus thienopyridine alone (1) ischemic stroke, (2) combined ischemic or hemorrhagic stroke, (3) composite outcome of stroke, myocardial infarction (MI), and cardiovascular death, (4) MI, (5) all-cause mortality, and (6) major or minor bleeding events...
January 16, 2018: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#18
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29327781/treatment-with-proton-pump-inhibitors-is-associated-with-increased-mortality-in-patients-with-pyogenic-liver-abscess
#19
D Bettinger, D Martin, S Rieg, M Schultheiss, N Buettner, R Thimme, T Boettler
BACKGROUND: Proton pump inhibitors (PPI) are often used in patients with gastro-esophageal reflux and peptic ulcer disease. A higher risk for infectious diseases and for pyogenic liver abscess has been reported in patients with prolonged PPI intake. Although many patients have ongoing PPI treatment after diagnosis of liver abscess, there are no data available that focus on the prognostic impact of PPI treatment in these patients. AIM: To analyse the effect of PPI treatment on mortality in patients with pyogenic liver abscesses...
January 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29327263/proton-pump-inhibitors-increase-the-susceptibility-of-mice-to-oral-infection-with-enteropathogenic-bacteria
#20
Eiichiro Yasutomi, Namiko Hoshi, Soichiro Adachi, Takafumi Otsuka, Lingling Kong, Yuna Ku, Haruka Yamairi, Jun Inoue, Tsukasa Ishida, Daisuke Watanabe, Makoto Ooi, Masaru Yoshida, Tomoya Tsukimi, Shinji Fukuda, Takeshi Azuma
BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Side effects including an increased risk of intestinal infections have been reported. It is assumed that PPIs can increase susceptibility to enteropathogens; however, the underlying mechanisms are unknown. Here in this study, we explored whether Lansoprazole (Laz), one of the PPIs, increases the susceptibility to enteropathogens, and further investigated the mechanism of it. METHODS: Mice were administered Laz intraperitoneally once daily and orally infected with Citrobacter rodentium (C...
January 11, 2018: Digestive Diseases and Sciences
keyword
keyword
119228
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"